TABLE 1.
Demographic characteristics of the study group
| Total a (n = 2290) | First dose | Total (n = 2189) | Second dose | |||||
|---|---|---|---|---|---|---|---|---|
| CoronaVac (n = 2097) | BioNTech (n = 183) | p value | CoronaVac (n = 2060) | BioNTech (n = 119) | p value | |||
| Sex n (%) | ||||||||
| Female | 1291 (56.4%) | 1192 (56.8%) | 91 (49.7%) | 0.057 | 1236 (56.5%) | 1170 (56.8%) | 58 (48.7%) | 0.085 |
| Male | 999 (43.6%) | 905 (43.2%) | 92 (50.3%) | 953 (43.5%) | 890 (43.2%) | 61 (51.3%) | ||
| Age Mean ± SD (Min‐Max) | 50.4 ± 17.9 (20–96) | 50.3 ± 18.3 (20–96) | 50.6 ± 11.4 (24–90) | 0.909 | 50.4 ± 18.1 (20–96) | 50.2 ± 18.4 (20–96) | 52.5 ± 10.9 (24–81) | 0.233 |
| Occupation n (%) | ||||||||
| Healthcare professional | 1167 (51.0%) | 1.124 (53.6%) | 43 (23.5%) | <0.001 | 1145 (52.3%) | 1115 (54.1%) | 30 (25.2%) | <0.001 |
| Other | 265 (11.6%) | 186 (8.9%) | 79 (43.2%) | 229 (10.5%) | 178 (8.6%) | 51 (42.9%) | ||
| Unemployed | 858 (37.5%) | 787 (37.5%) | 61 (33.3%) | 815 (37.2%) | 767 (37.2%) | 38 (31.9%) | ||
| Comorbidities | 1050 (45.9%) | 975 (46.5%) | 66 (36.1%) | <0.001 | 1015 (46.4%) | 958 (46.5%) | 48 (40.3%) | 0.189 |
| Hypertension + CAD + CHF | 679 (29.7%) | 631 (30.1%) | 40 (21.9%) | <0.001 | 660 (30.2%) | 621 (30.1%) | 31 (26.1%) | 0.343 |
| Diabetes mellitus | 339 (14.8%) | 310 (14.8%) | 24 (13.1%) | 0.006 | 325 (14.8%) | 304 (14.8%) | 16 (13.4%) | 0.694 |
| CD, ED, AD | 211 (9.2%) | 196 (9.3%) | 14 (7.7%) | 0.746 | 203 (9.3%) | 192 (9.3%) | 10 (8.4%) | 0.737 |
| Oncological diseases | 45 (2.0%) | 40 (1.9%) | 4 (2.2%) | 0.212 | 41 (1.9%) | 37 (1.8%) | 3 (2.5%) | 0.478 |
| Other | 179 (7.8%) | 170 (8.1%) | 9 (4.9%) | 0.199 | 172 (7.9%) | 167 (8.1%) | 5 (4.2%) | 0.125 |
| Allergic disease history | 402 (17.6%) | 370 (17.6%) | 29 (15.8%) | 0.484 | 382 (17.5%) | 361 (17.5%) | 18 (15.1%) | 0.502 |
| Asthma | 120 (5.2%) | 113 (5.4%) | 5 (2.7%) | 0.033 | 119 (5.4%) | 112 (5.4%) | 5 (4.2%) | 0.561 |
| Urticaria/angioedema | 81 (3.5%) | 72 (3.4%) | 9 (4.9%) | 0.483 | 74 (3.4%) | 71 (3.4%) | 3 (2.5%) | 0.796 |
| Rhinoconjunctivitis | 212 (9.3%) | 200 (9.5%) | 11 (6.0%) | 0.287 | 204 (9.3%) | 196 (9.5%) | 7 (5.9%) | 0.185 |
| Drug/food allergy | 108 (4.7%) | 96 (4.6%) | 1 (6.0%) | 0.498 | 104 (4.8%) | 94 (4.6%) | 9 (7.6%) | 0.134 |
| Atopic dermatitis | 70 (3.1%) | 65 (3.1%) | 3 (1.6%) | 0.004 | 67 (3.1%) | 62 (3.0%) | 3 (2.5%) | 1.000 |
Abbreviations: AD, autoimmune diseases; CAD, coronary artery disease; CD, connective diseases; CHF, congestive heart failure; ED, endocrinological diseases.
a
Type of vaccine applied not known for 10 participants.